Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47,898,935
-
Total 13F shares
-
50,443,395
-
Share change
-
-1,332,234
-
Total reported value
-
$5,047,277,313
-
Put/Call ratio
-
289%
-
Price per share
-
$100.05
-
Number of holders
-
277
-
Value change
-
-$147,988,434
-
Number of buys
-
128
-
Number of sells
-
154
Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q4 2018
As of 31 Dec 2018,
HAEMONETICS CORP - Common Stock (HAE) was held by
277 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,443,395 shares.
The largest 10 holders included
BlackRock Inc., Vanguard Group Inc, WELLINGTON MANAGEMENT GROUP LLP, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, Jackson Square Partners, LLC, Neuberger Berman Group LLC, Capital Research Global Investors, HealthCor Management, L.P., and DIMENSIONAL FUND ADVISORS LP.
This page lists
277
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.